IN-NTT/NTT-DATA
23.5.2024 16:06:30 CEST | Business Wire | Press release
NTT, a leading global technology and business solutions provider, and NTT DATA continue to expand innovative use of racing data to improve fan experiences across the NTT INDYCAR SERIES, including this year’s Indianapolis 500.
NTT is the parent company of NTT DATA, and they serve together as Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway (IMS), the Indianapolis 500, and NASCAR Brickyard weekend.
Through 140-plus sensors on each racecar, NTT DATA captures and analyzes more than 8 billion racing datapoints in the NTT Smart Solutions Platform. Leveraging advanced AI and predictive analytics, the company shares near-real-time insights and visualizations to fans both onsite and remotely for enhanced storytelling of key moments during events including head-to-head overtaking, race strategies, race winner predictions and more. Additionally, the 300,000-plus fans onsite for the race benefit from data on wait times and flow across the 600-plus acre venue calibrated every 30 seconds.
SMART Venues Improve the Fan Experience
Fans at the Indianapolis 500 or other events at the Indianapolis Motor Speedway can experience NTT DATA Smart Venue technology, sustainability solutions and live race data at the Pagoda command displays. For example, AI-enabled optical detection technologies improve security and traffic flow, and when combined with digital ticketing, provide real-time and future prediction wait times at the event gates and concessions. This allows fans at the world’s largest single-day sporting event to move through the venue as safely and efficiently as possible.
AI-enabled Racing Insights
Whether at the racetrack, at home or on the go, fans of the NTT INDYCAR SERIES can also tap into the INDYCAR App Powered by NTT DATA to stay up to date on all of the latest developments. The App allows fans to get even closer to the action with real-time, AI and advanced analytics providing racing insights that include live scoring and viewing of the drivers in action courtesy of 15 in-car cameras. The App, which historically engages more than 70,000 users on race days, is available for download from the iOS App Store and Google Play.
NTT DATA also continues to enable other similar innovative experiences to benefit fans and increase engagement across all mediums, via social media, the web and television or streaming broadcast, through reliable technology and services that deliver deeper data insights.
Race Like the Pros
This year, a new limited racing demonstration will leverage Embodied Knowledge technology from NTT R&D. Embodied Knowledge powers simulators that blend physical sensations with digital innovation, allowing users to precisely experience a track as driven by a professional driver. Beyond the experience of traditional simulators, Embodied Knowledge adds the actual feel and performance of the professional driver at high speeds at the Indianapolis Motor Speedway including realistic steering wheel forces and car behavior like vibrations and forces exerted on seat, users can synchronize their movements with that of a professional driver via XR.
NTT Embodied Knowledge technology is being explored for future use cases including medical surgery training, coaching and fan experiences in sports. Future applications include employee training across retail, education, and manufacturing, as well as enabling AI-robots to learn how to move and react the way humans do to perform tasks from restocking shelves to in-home caregiving. The effort is part of the more than $3.6B NTT invests each year in research and development, uncovering innovations that have commercial impact for their customers.
“The Indianapolis 500 is the pinnacle of racing that leverages refined Embodied Knowledge where firsthand the movements of racers can be felt to understand what Embodied Knowledge truly means. Through various sensing technologies, we aim to technically recreate these movements and sensations.” said Kota Hidaka, Vice President, Head of NTT Human Informatics Laboratories.
To learn more about the NTT INDYCAR SERIES, visit: https://us.nttdata.com/en/about-us/content/ntt-indycar-series.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523988191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
